These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 18045190)

  • 1. Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling.
    Bianco R; Damiano V; Gelardi T; Daniele G; Ciardiello F; Tortora G
    Curr Pharm Des; 2007; 13(33):3358-67. PubMed ID: 18045190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR as a potential target for the treatment of pancreatic cancer: dilemma and controversies.
    Nedaeinia R; Avan A; Manian M; Salehi R; Ghayour-Mobarhan M
    Curr Drug Targets; 2014; 15(14):1293-301. PubMed ID: 25429712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies.
    Zhou J; Ji Q; Li Q
    J Exp Clin Cancer Res; 2021 Oct; 40(1):328. PubMed ID: 34663410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer.
    Gui T; Shen K
    Cancer Epidemiol; 2012 Oct; 36(5):490-6. PubMed ID: 22818908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy.
    van der Veeken J; Oliveira S; Schiffelers RM; Storm G; van Bergen En Henegouwen PM; Roovers RC
    Curr Cancer Drug Targets; 2009 Sep; 9(6):748-60. PubMed ID: 19754359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
    Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y
    Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of additional inhibition of human epidermal growth factor receptor 2 with the bispecific tyrosine kinase inhibitor AEE788 on the resistance to specific EGFR inhibition in glioma cells.
    Berezowska S; Diermeier-Daucher S; Brockhoff G; Busch R; Duyster J; Grosu AL; Schlegel J
    Int J Mol Med; 2010 Nov; 26(5):713-21. PubMed ID: 20878094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-talk between EGFR and IL-6 drives oncogenic signaling and offers therapeutic opportunities in cancer.
    Ray K; Ujvari B; Ramana V; Donald J
    Cytokine Growth Factor Rev; 2018 Jun; 41():18-27. PubMed ID: 29680500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiscale modeling reveals angiogenesis-induced drug resistance in brain tumors and predicts a synergistic drug combination targeting EGFR and VEGFR pathways.
    Liang W; Zheng Y; Zhang J; Sun X
    BMC Bioinformatics; 2019 May; 20(Suppl 7):203. PubMed ID: 31074391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines.
    De Pauw I; Lardon F; Van den Bossche J; Baysal H; Fransen E; Deschoolmeester V; Pauwels P; Peeters M; Vermorken JB; Wouters A
    Mol Oncol; 2018 Jun; 12(6):830-854. PubMed ID: 29603584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy.
    Raymond E; Faivre S; Armand JP
    Drugs; 2000; 60 Suppl 1():15-23; discussion 41-2. PubMed ID: 11129168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Signal transduction pathways of the epidermal growth factor receptor in colorectal cancer and their inhibition by small molecules.
    Efferth T
    Curr Med Chem; 2012; 19(33):5735-44. PubMed ID: 23033949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy.
    Bianco R; Troiani T; Tortora G; Ciardiello F
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S159-71. PubMed ID: 16113092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual Targeting of Epidermal Growth Factor Receptor and HER3 by MEHD7945A as Monotherapy or in Combination with Cisplatin Partially Overcomes Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines.
    De Pauw I; Wouters A; Van den Bossche J; Deschoolmeester V; Baysal H; Pauwels P; Peeters M; Vermorken JB; Lardon F
    Cancer Biother Radiopharm; 2017 Sep; 32(7):229-238. PubMed ID: 28910149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies.
    Tortora G; Bianco R; Daniele G; Ciardiello F; McCubrey JA; Ricciardi MR; Ciuffreda L; Cognetti F; Tafuri A; Milella M
    Drug Resist Updat; 2007 Jun; 10(3):81-100. PubMed ID: 17482503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms.
    Yamaoka T; Ohba M; Ohmori T
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29140271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies for overcoming inherent and acquired resistance to EGFR inhibitors by targeting downstream effectors in the RAS/PI3K pathway.
    Weickhardt AJ; Tebbutt NC; Mariadason JM
    Curr Cancer Drug Targets; 2010 Dec; 10(8):824-33. PubMed ID: 20718704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rational design of potent and selective EGFR tyrosine kinase inhibitors as anticancer agents.
    Ghosh S; Liu XP; Zheng Y; Uckun FM
    Curr Cancer Drug Targets; 2001 Aug; 1(2):129-40. PubMed ID: 12188886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck.
    Campbell NP; Hensing TA; Bhayani MK; Shaikh AY; Brockstein BE
    Expert Rev Anticancer Ther; 2016 Aug; 16(8):847-58. PubMed ID: 27400139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting ErbB receptors in high-grade glioma.
    Berezowska S; Schlegel J
    Curr Pharm Des; 2011; 17(23):2468-87. PubMed ID: 21827413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.